Rablet IV Injection contains the active component Rabeprazole. This medication belongs to a class of drugs known as proton pump inhibitors (PPIs). It is commonly prescribed to treat excess stomach acid production conditions, such as gastroesophageal reflux disease (GERD), gastric ulcers, and Zollinger-Ellison syndrome. Zollinger-Ellison syndrome is a rare condition characterized by the overproduction of stomach acid. Rablet IV Injection helps relieve excess stomach acid production symptoms, such as heartburn, regurgitation, chest pain, and acid indigestion. Reducing the amount of acid in the stomach can alleviate discomfort and improve quality of life. This medication is contraindicated in individuals with known hypersensitivity or allergic reactions to Rablet IV Injection or other ingredients in the formulation. Signs of an allergic reaction may include rash, itching, swelling, severe dizziness, or difficulty breathing. It is not typically recommended for children under 18, as its safety and efficacy in this population have not been well established. Alternative treatment options may be considered for pediatric patients with similar conditions. Rablet IV Injection can potentially increase the blood levels of methotrexate, a medication used to treat certain cancers and autoimmune diseases. Co-administration of this medication and high-dose methotrexate is not recommended due to the potential for increased toxicity of methotrexate.